Graves´ ophthalmopathy
Conditions
Brief summary
1. Clinical activity score (CAS) and progression to severe GO after 6 months of treatment with diclofenac, simvastatin or no additional treatment.
Detailed description
1. Modified CAS is better than CAS in discriminating changes in activity score? 2. Conjunctival thickness with optical coherence tomography after 3 and 6 months treatment with diclofenac, simvastatin or no additional treatment 3. Quality of life after 6 months treatment with diclofenac, simvastatin or no additional treatment 4. Changes in TRAb and TPOAb after 3 and 6 months treatment with diclofenac, simvastatin or no additional treatment 5. Novel markers of active ophthalmopathy
Interventions
DRUGSIMVASTATIN
DRUGDICLOFENAC
Sponsors
Region Skane
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Clinical activity score (CAS) and progression to severe GO after 6 months of treatment with diclofenac, simvastatin or no additional treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Modified CAS is better than CAS in discriminating changes in activity score? 2. Conjunctival thickness with optical coherence tomography after 3 and 6 months treatment with diclofenac, simvastatin or no additional treatment 3. Quality of life after 6 months treatment with diclofenac, simvastatin or no additional treatment 4. Changes in TRAb and TPOAb after 3 and 6 months treatment with diclofenac, simvastatin or no additional treatment 5. Novel markers of active ophthalmopathy | — |
Countries
Sweden
Outcome results
None listed